TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05914649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV normal saline (999 mL infusion)
Description: 999 mL of IV normal saline will be infused intravenously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV normal saline (50 mL infusion)
Description: 50 mL of IV normal saline will be infused intravenously as a placebo control.
Study: NCT05694715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given intravenously (IV)
Study: NCT06595706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucid-21-302
Description: Capsule containing a small molecule inhibitor of hypercitrullination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing only Silicified Microcrystalline Cellulose
Study: NCT05436860

Intervention type: DEVICE
Intervention: liver ultrasound
Description: At the time of access to the emergency room, a cohort of male and female patients aged 18 or over will be consecutively recruited with green or white color coded triage.~patients who agree to participate in the study will undergo liver ultrasound. Patients who test negative on ultrasound evaluation for liver hyperechogenicity will be part of the control group.

Intervention type: DEVICE
Intervention: liver ultrasound
Description: At the time of access to the emergency room, a cohort of male and female patients aged 18 or over will be consecutively recruited with green or white color coded triage.~patients who agree to participate in the study will undergo liver ultrasound. Patients who test negative on ultrasound evaluation for liver hyperechogenicity will be part of the control group.
Study: NCT06663813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Utilizing the Health Belief model, educational materials detailing diabetes risk factors to address perceived susceptibility, diabetes severity and complications to address perceived severity, and PCP follow-up information and medication assistance programs to address perceived barriers will be provided.
Study: NCT06597370

Intervention type: OTHER
Intervention: Gene expression mRNA of IgG anti-spike
Description: b) Peripheral venous blood samples (3 ml per occasion) will be taken from all participants. They will be carried out on days 30,60 and 120 after completion of the COVID-19 vaccination schedule.~c) Sample processing:~* tRNA extraction from all samples.~* cDNA synthesis~* Real time PCR performance.

Intervention type: OTHER
Intervention: Gene expression mRNA of IgG anti-spike
Description: b) Peripheral venous blood samples (3 ml per occasion) will be taken from all participants. They will be carried out on days 30,60 and 120 after completion of the COVID-19 vaccination schedule.~c) Sample processing:~* tRNA extraction from all samples.~* cDNA synthesis~* Real time PCR performance.

Intervention type: OTHER
Intervention: Gene expression mRNA of IgG anti-spike
Description: b) Peripheral venous blood samples (3 ml per occasion) will be taken from all participants. They will be carried out on days 30,60 and 120 after completion of the COVID-19 vaccination schedule.~c) Sample processing:~* tRNA extraction from all samples.~* cDNA synthesis~* Real time PCR performance.

Intervention type: OTHER
Intervention: Gene expression mRNA of IgG anti-spike
Description: b) Peripheral venous blood samples (3 ml per occasion) will be taken from all participants. They will be carried out on days 30,60 and 120 after completion of the COVID-19 vaccination schedule.~c) Sample processing:~* tRNA extraction from all samples.~* cDNA synthesis~* Real time PCR performance.
Study: NCT06614725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: 1 dose of RSVPreF3 OA investigational vaccine administered intramuscularly on Day 1 to participants in OA-RSV and Adults-AIR-RSV groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: 1 dose of RSVPreF3 OA investigational vaccine administered intramuscularly on Day 1 to participants in OA-RSV and Adults-AIR-RSV groups.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose of placebo (saline solution) administered intramuscularly on Day 1 to participants in OA-Placebo and Adults-AIR-Placebo groups.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose of placebo (saline solution) administered intramuscularly on Day 1 to participants in OA-Placebo and Adults-AIR-Placebo groups.
Study: NCT06598930

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine follow-up
Description: As recommended: a vascular doctor exclusively, face-to-face consultations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive follow-up
Description: a vascular physician and an IPA, with alternating face-to-face and remote consultations.
Study: NCT06624267

Intervention type: DIAGNOSTIC_TEST
Intervention: PET
Description: PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Two 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. One 5-minute scan is conducted of the brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).
Study: NCT06101771

Intervention type: DIAGNOSTIC_TEST
Intervention: echoCARDIOGRAPHY
Description: Assessment of epicardial fat thickness in children with familial dyslipidemia
Study: NCT05694715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given intravenously (IV)
Study: NCT05480514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST LENS
Description: etafilcon A with cosmetic pattern

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST LENS
Description: etafilcon A with cosmetic pattern

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL LENS
Description: Acuvue 1-Day Define Fresh Honey

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL LENS
Description: Acuvue 1-Day Define Fresh Honey
Study: NCT04935944

Intervention type: RADIATION
Intervention: CBCT radiation
Description: CBCT scanning
Study: NCT04847986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acceptance and commitment therapy (ACT)
Description: Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The control group will receive care as usual with psychoeducation materials provided.
Study: NCT05015712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate intensity continuous training
Description: Moderate intensity continuous training was scheduled 3 times per week for 3 months. Every sessions included warm-up (\<50% target intensity for 2 min then gradually increasing load 1-10 W/min up to 100% target intensity for 5-10 min), exercise phase (100% target intensity (heart rate at anaerobic threshold±5) starting with 20 min and gradually lengthening up to 45 min in the 1 month as well as 45 min in another 2 months), cool down with gradual reduction of load within 3 min. The target intensity will be determined by the heart rate at anaerobic threshold measured by cardiopulmonary exercise test (CPET). The intensity will be adjusted after implementation of CPET and will keep at a minimum intensity, gradually increasing to the maximum intensity every month. Moreover, patients will be instructed to complete 2 supervised sessions and 1 home-based session during the 1 month and then to continue 3 home-based session for a further 2 months.
Study: NCT05694715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given intravenously (IV)
Study: NCT06334900

Intervention type: OTHER
Intervention: GAD patients
Description: Describe the clinical and demographic characteristics of patients with anti-GAD65 antibody associated cerebellar ataxia.
Study: NCT06401031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press Needle
Description: Press needle is patch-type acupuncture needle which has a very small needle. This is placed onto acupuncture point and give a simultaneous stimulation, which is held in place with a small, sterile surgical adhesive patch.
Study: NCT05084625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digitized support
Description: Access to information about the disease, treatment, side effects and self-care
Study: NCT04766697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk-Reduction Sessions
Description: The 8-session intervention protocol emphasizes cognitive-behavioral interventions for anger management, conflict resolution, reducing sexual risk behavior, substance use, and enhancement of couple functioning.
Study: NCT06788691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Administered at 1 mg/kg once every 3 weeks
Study: NCT06790173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy training for physical activity
Description: STPA is a home-based rehabilitation that guides stroke participants to implement strategy training for addressing barriers to physical activity engagements. Participants learn and practice meta-cognitive strategies (to set a goal, to make a plan, to do the plan, to check the performance of the plan) throughout the intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: PA program consists of a warm-up for 5 minutes, an aerobic exercise program for 30-40 minutes, a multicomponent exercise program (resistance and balance training) for 10-20 minutes, and finally, a cooling down program for 5 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Stroke-related information and knowledge that includes stroke subtypes and their etiology, risk factors of primary and secondary stroke, healthy lifestyles, common sequala, and adaptive skills for impaired functions are provided.
Study: NCT06788457

Intervention type: DEVICE
Intervention: Exhaled Breath Condensate
Description: Measurement of hydrogen peroxide in exhaled breath

Intervention type: DEVICE
Intervention: Exhaled Breath Condensate
Description: Measurement of hydrogen peroxide in exhaled breath
Study: NCT06789718

Intervention type: DIETARY_SUPPLEMENT
Intervention: GABA Probiotic Lactiplantibacillus plantarum Lp815 (5 Billion cfu/dose)
Description: 75 participants will be randomized into the study product group.

Intervention type: OTHER
Intervention: Placebo
Description: 75 participants will be randomized into the placebo group.

Intervention type: DIAGNOSTIC_TEST
Intervention: Optional Sub-Study: Neurotransmitter Urine Test
Description: 20 participants who opt-in to the sub-study will provide urine tests during baseline, day 2, day 4, day 7, day 14, day 28, and day 42 while simultaneously participating in the main-study.
Study: NCT06579612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized follow-up and support
Description: After a pulmonary rehabilitation program, an interview with a professional will enable the professional to identify the barriersand enablers of physical activity engagement, and to identify (with the patient) a plan for maintaining a physical activities adapted in daily life. Adapted solutions will then be proposed.
Study: NCT06789159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK-2019
Description: VK-2019 will be administered daily starting on day 1 of cycle 1 (D1C1). Dose cohort A will dose at 600 mg dose cohort B 1200 mg and dose cohort C 1800 mg. Treatment cycles will repeat every 28 days , in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK-2019
Description: VK-2019 will be administered daily starting on day 1 of cycle 1 (D1C1). Dose cohort A will dose at 600 mg dose cohort B 1200 mg and dose cohort C 1800 mg. Treatment cycles will repeat every 28 days , in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK-2019
Description: VK-2019 will be administered daily starting on day 1 of cycle 1 (D1C1). Dose cohort A will dose at 600 mg dose cohort B 1200 mg and dose cohort C 1800 mg. Treatment cycles will repeat every 28 days , in the absence of disease progression or unacceptable toxicity.
Study: NCT06037252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Administered SC
Study: NCT05955534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TPUG
Description: Tracheostomy shall utilize any FDA approved device for the performance of percutaneous dilatational tracheostomy. PUG shall be performed using the only FDA-cleared device for ultrasound gastrostomy, the PUMA-G System.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PEG
Description: Each site will perform the procedures of gastrostomy placement using the devices according to their institutional policy and guidelines.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PRG
Description: Each site will perform the procedures of gastrostomy placement using the devices according to their institutional policy and guidelines.
Study: NCT05048017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib, 120 mg, once a day, 3 weeks on/1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Camrelizumab: 200mg (BW ≥ 50 kg) or 3 mg/kg (BW \< 50 kg) Toripalimab: 240mg is given through intravenous drip every 3 weeks on Day 1 of each course of treatment.~Pembrolizumab: 200mg is given through intravenous drip every 3 weeks.
Study: NCT05900934

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Releasing Group
Description: Using a subjective 7/10 target numeric rating scale rating (0 representing no discomfort and 10 representing maximum discomfort), the intensity of foam roller application can be determined. This intensity defines an application intensity that is mildly painful for the participant and appropriate according to previous literature.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Myofascial Releasing Group
Description: The severity of the application is not felt at all according to the numerical rating scale of 0/10.
Study: NCT05315557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: 1mg/24 hour and titrate according to MAP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vasopressin
Description: 0.03 U/hour and titrate according to MAP
Study: NCT05867862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test
Description: A dental consultation of 30 to 45 minutes will be added to the annual visit with a dentist.~If dental treatments are needed, they will be done at the same time, or they will be programmed for another time at the center of dental care (CSD).~Due to the fact that most patient live far away from Nantes and the hospital, teleconsultation for patient in the test groups will happen every 2 months
Study: NCT05163119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commercial Cellphone-Blocking App (Active)
Description: The Fleetsafer app, which is a commercial cellphone app that uses a cellphone's standard sensors and function to block handheld cellphone use while driving, will be downloaded on the participant's smartphone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Driving Mode
Description: Apple's Do Not Disturb driving mode provided by Apple for iPhones or Google Do Not Disturb, Verizon Messages +, Android Auto or have another app, called LifeSaver installed on their Android phone (collectively referred to as driving modes; the specific driving mode for participants in this arm will be determined based on smartphone type and service provider).
Study: NCT05703022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Description: The intervention will start between 7 and 21 days after heart valve surgery. While hospitalized the participants will perform supervised aerobic interval training comprised 4x4 minute, 3 times per week. Intensity will start at 60% of maximum heart rate in the first week, around 13-14 in Borg RPE-Scale. The workload will be gradually increased as the participant tolerance improves, but not above 85% of maximum heart rate or 16-17 in Borg RPE Scale.
Study: NCT05857774

Intervention type: OTHER
Intervention: Sonographic measurements
Description: Diaphragm thickness, diaphragm tidal thickening fraction, abdominal muscle thickness, rectus femoris cross-sectional area, maximal diaphragm thickening fraction, abdominal muscle thickening fraction

Intervention type: OTHER
Intervention: Sonographic measurements
Description: Diaphragm thickness, diaphragm tidal thickening fraction, abdominal muscle thickness, rectus femoris cross-sectional area, maximal diaphragm thickening fraction, abdominal muscle thickening fraction

Intervention type: OTHER
Intervention: Sonographic measurements
Description: Diaphragm thickness, diaphragm tidal thickening fraction, abdominal muscle thickness, rectus femoris cross-sectional area, maximal diaphragm thickening fraction, abdominal muscle thickening fraction

Intervention type: OTHER
Intervention: Physiological measurements
Description: Airway occlusion pressure, maximal inspiratory pressure, muscle research council score

Intervention type: OTHER
Intervention: Physiological measurements
Description: Airway occlusion pressure, maximal inspiratory pressure, muscle research council score

Intervention type: OTHER
Intervention: Physiological measurements
Description: Airway occlusion pressure, maximal inspiratory pressure, muscle research council score

Intervention type: OTHER
Intervention: Biological measurements
Description: Skeletal troponin-I

Intervention type: OTHER
Intervention: Biological measurements
Description: Skeletal troponin-I

Intervention type: OTHER
Intervention: Biological measurements
Description: Skeletal troponin-I
Study: NCT06431321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tabudira Parenting Intervention for Early Childhood Development
Description: 2 session programme delivered weekly over 2 weeks using group-based delivery aimed at reducing child maltreatment, improving parenting behaviours and parent's mental health.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional guide for younger children
Description: 2 session programme delivered weekly over 2 weeks aimed at providing parents with nutritional education to help provide maximum nutrition to the growing child
Study: NCT06037252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06788600

Intervention type: DRUG
Intervention: EBV mRNA vaccine (WGc-043)
Description: Each subject will be infused with EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.~The specific dose of mRNA vaccine will be determined according to the experimental group.

Intervention type: DRUG
Intervention: EBV mRNA vaccine (WGc-043)
Description: Each subject will be infused with EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.~The specific dose of mRNA vaccine will be determined according to the experimental group.
Study: NCT06049342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NCR100 injection
Description: Subjects will receive a one-dose intra-articular NCR100 injection.
Study: NCT06549972

Intervention type: OTHER
Intervention: Acute Ischemic Stroke
Description: first-ever anterior circulation AIS (Acute Ischemic Stroke)
Study: NCT06240182

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: Surgery performed using conventional rotary burs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: piezoelectric device
Description: surgery performed using piezoelectric device.
Study: NCT05550181

Intervention type: BEHAVIORAL
Intervention: intraoperative mechanical ventilation with hypocapnia (etCO2 < 35 mm Hg)
Description: A patient is considered 'hypocapnic' if the etCO2 was \< 35 mm Hg at any point during surgery, from start of the study till end of the study and classified as 'without hypocapnia' otherwise. In case of a missing value immediately before extubation, we will use the values as reported in the last hour of surgery.
Study: NCT05415007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GOLD Program
Description: Participant will receive a 2-hour interventional session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Participant will receive treatment-As-Usual which consist of information about diagnosis routinely-disseminated by personnel and providers.
Study: NCT05431790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorbable interface screws manufactured by Natong Biotechnology
Description: Anterior cruciate ligament reconstruction uses absorbable interface screws manufactured by Natong Biotechnology.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable interface screws manufactured by INION.
Description: Reconstruction of anterior cruciate ligament using Inion Oy absorbable interface scews from INION, Finland